The center for innovation and translation of point of care technologies for equitable cancer care (citec)
Active Cooperative Agreement Awarded Last action
- Award ID
- U54EB034652
- Recipient
-
William Marsh Rice University UEI K51LECU1G8N3
- Awarding agency
-
National Institute of Biomedical Imaging and Bioenginering
National Institutes of Health, Department of Health and Human Services
- Obligated
- $12,961,457
Award facts
- Assistance listing
- 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health
- Completion date 63% complete
- Place of performance
- Houston, TX 77005, USA
Award details come from USAspending.gov.
Description
- Abstract
- Cancer is the first or second leading cause of premature death in 134 of 183 countries, and IT is estimated that global incidence of cancer will increase by 50% from 2018 to 2040. The number of cases is projected to double in countries with low human development index; these countries have the least resources and infrastructure to adequately care for cancer patients. Disparities exist within countries; in the US, racial and ethnic minorities and other medically underserved populations share a disproportionate burden for many types of cancer. Most cancers can be cured if detected early and treated effectively. To reduce premature death, the world health organization recommends implementing early cancer detection and prevention programs at the primary care level. Yet, existing tests for early cancer detection are too complex and/or expensive to implement in primary care settings, particularly in medically underserved areas. We will establish the center for innovation and translation of point-of-care technologies for equitable cancer care (citec) to identify high- priority clinical needs for POC cancer technologies; to accelerate development of effective, affordable technologies to meet these needs; to evaluate and improve the clinical and public health impact of POC technologies in diverse settings; and to train developers and users to create and disseminate more equitable POC technologies. Citec will prioritize development of POC tests to detect cancers that arise in epithelial surfaces. Initially, we will focus on sites accessible for early detection because this is where POC technologies can have the most immediate impact. Targeted organ sites include the uterine cervix, gastro-intestinal tract (esophagus, stomach, colon, rectum, anus), and oral cavity; cancers in these sites account for 26% of global cases and 29% of global cancer deaths. Citec builds on the highly productive 15-year collaboration between rice university, the university of texas MD anderson cancer center, baylor college of medicine, and the university of texas health science center at houston to develop and translate novel POC technologies to improve cancer care in both low- and high-resource settings. Joining with collaborators in brazil at the university of SAO paulo and barretos cancer hospital and partners in mozambique at the universidade eduardo mondlane and ministry of health, we will create a collaborative center to support technology development and engage and support a global community of investigators dedicated to creating and scaling POC technologies for equitable cancer screening and diagnosis to facilitate early treatment. Citec will support development of POC technologies to promote high priority topics of NIH cancer research, including precision approaches to prevention, screening and early detection, reducing disparities in cancer outcomes, and building a diverse workforce able to translate POC technologies from research and development to equitable implementation. Citec will have a major impact on equitable prevention, diagnosis and early treatment of cancer in the US and worldwide, and will work with the poctrn network to build a strong team of global partners to strengthen and sustain POC technology development.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $13,791 | |
| Amendment | $24,754 | |
| Amendment | $1,261,456 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $13,790 | |
| Amendment | $24,755 | |
| Amendment | $13,790 | |
| Amendment | $24,755 | |
| Amendment | $24,755 | |
| Amendment | $13,790 | |
| Amendment | $1,261,455 | |
| Amendment | $1,261,455 | |
| Amendment | $1,261,455 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,300,000 | |
| Amendment | $1,300,000 | |
| Amendment | $1,300,000 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,300,000 | |
| Original award | $1,300,000 |
Show all 39
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| The General Hospital Corporation | $137,775 | |
| University Of California, Berkeley | $150,000 | |
| University Of Rochester | $146,037 | |
| Baylor College Of Medicine | $149,950 | |
| University Of Texas At Austin | $124,672 | |
| The Univeristy Of Texas M.d. Anderson Cancer Center | $34,042 | |
| Baylor College Of Medicine | $181,750 | |
| Baylor College Of Medicine | $100,000 | |
| Amplifidx Inc. | $50,000 | |
| Baylor College Of Medicine | $209,627 | |
| University Of Texas At Austin | $49,981 | |
| University Of Arizona | $49,999 | |
| The Univeristy Of Texas M.d. Anderson Cancer Center | $30,742 | |
| Subrecipient not on record | $44,119 | |
| Miher Mozambique Institute For Health Education & Research | $37,767 | |
| Baylor College Of Medicine | $50,000 | |
| The Univeristy Of Texas M.d. Anderson Cancer Center | $30,135 | |
| Baylor College Of Medicine | $182,713 |
Show all 18
Quick answers
Who received award U54EB034652?
U54EB034652 was awarded to William Marsh Rice University by National Institute of Biomedical Imaging and Bioenginering (National Institutes of Health) on September 13, 2023.
How much is award U54EB034652 worth?
$12,961,457 has been obligated on U54EB034652.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award